BioStem Technologies today announced the submission of applications for three of its dehydrated placental membrane allograft products to the Centers for Medicare and Medicaid Services (CMS), in process to be granted Q-Codes.
The Company announced that it embarked on a new initiative to define its two distinct business pillars, BioStem Technologies and BioStem Life Sciences. The new strategic focus of BioStem Technologies is to identify, develop and market the life changing regenerative biologics, formally spearheaded by BioStem Life Sciences. This includes an all new biologic therapeutic pipeline focused on Acute Respiratory Distress Syndrome (ARDS) and Osteoarthritis (OA). BioStem Technologies will also assume the sales and distribution of the RHEO™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC brands.
Like most organizations around the world, BioStem has been closely monitoring the COVID-19 pandemic and its impact on patients, healthcare professionals, and our community. We continue to monitor and respond to this rapidly changing situation based on updates and recommendations from the CDC and local health officials, so please visit this page for updates.
